Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 23Melanoma 21Carcinoma, Renal Cell 21Neoplasms 8Lung Neoplasms 8Colorectal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Prostatic Neoplasms 7Neoplasm Metastasis 6Carcinoma, Transitional Cell 6Carcinoma, Hepatocellular 6Stomach Neoplasms 5Rectal Neoplasms 5Hodgkin Disease 5Adenocarcinoma Of Esophagus 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Nasopharyngeal Carcinoma 4Endometrial Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Pancreatic Neoplasms 3Oropharyngeal Neoplasms 3Multiple Myeloma 3Leukemia, Myeloid, Acute 3Esophageal Neoplasms 3Colonic Neoplasms 3Brain Neoplasms 3Anus Neoplasms 3

Interventions

tazemetostat 1selinexor 1pazopanib 1Proton Therapy 1Nivolumab 1Ipilimumab 1Ifosfamide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nerve Sheath Neoplasms × Nivolumab × 30 days × Clear all
NCT04465643 2026-05-29

Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
13 enrolled

Nerve Sheath Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡